Novartis has inked a deal with China-based biotech Sironax that gives the pharma the exclusive option to acquire the ...

Mendaera has claimed an FDA clearance for its handheld robotic needle delivery system, for precision placement guided by ...

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...

Jasper Therapeutics’ dud drug lot has cost half of the biotech's employees their jobs. | Jasper Therapeutics’ dud drug lot ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

At the halfway mark last year, 97 layoff rounds were reported, marking a 32% year-over-year increase for the first half of ...

The FDA has cleared its first cuffless blood pressure monitor that will be available over-the-counter, with the Hilo ...

Through the Mango partnership, Veeda will use the AI company’s Querent platform to streamline procedures, improve data management and increase diversity of research participants, according to a July 8 ...

KJ Muldoon recently made history by becoming the first patient to receive a personalized CRISPR gene therapy, designed specifically for the genetic mutations causing his rare metabolic disease. | KJ ...

Taiho-developed TAS-205 is designed to selectively inhibit hematopoietic prostaglandin D synthase (HPGDS), an enzyme related ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...